Core Insights - Insight Molecular Diagnostics Inc. has submitted GraftAssureDx, a kitted dd-cfDNA assay, to the FDA for regulatory review, marking a significant milestone after 12 years of clinical development and 3 years of technical product development [1] - The company has seen a doubling in interest from transplant centers, now engaging with 37 centers in the U.S. and 11 internationally, which represents over 25% of annual transplants in the U.S. [3][4] - The addressable market for regulated transplant rejection testing is estimated at around $2 billion, with the company positioned to lead in this emerging market [4][5] FDA Submission and Market Readiness - The FDA has a 150-day review process for de novo submissions, and the company anticipates receiving authorization within this timeframe [5] - The company has prepared a review-ready submission with sufficient analytical data and clinical evidence to support the assay's safety and effectiveness [8] - The company expects to receive U.K. CE marking via self-certification in Q2 2026 [6] Financial Overview - For the full year 2025, the company reported revenue of $4.1 million, up from $1.9 million in 2024, with Q4 2025 revenues at $1.1 million [30] - The gross profit for 2025 was $2.3 million, reflecting a gross margin of 56.7%, compared to a gross profit of $740,000 in the previous year [32] - Operating expenses for 2025 totaled $53.4 million, including significant non-cash impairment losses [32] Research and Development - Research and development expenses increased by 62% year-over-year to $15.9 million, reflecting investments in kitted product development [32] - The company is also focusing on expanding GraftAssure's utility into heart transplantation, supported by a recent $26 million financing [6][12] Clinical Utility and Market Trends - The company believes that the organ transplant rejection testing market is shifting towards active management of patients post-transplant, enabling earlier detection of organ rejection [17] - The GraftAssure assay is designed to measure both absolute and relative quantities of dd-cfDNA, potentially improving the detection of T-cell mediated rejection [21][22] - The company anticipates that the demand for decentralized molecular testing will continue to grow, supported by emerging clinical data and publications [5][16] Strategic Goals for 2026 - The company aims to transition into a commercialization-stage company in 2026, with goals including obtaining regulatory approval for GraftAssureDx and commencing sales of the research-use-only version of its kits [12][13] - The company plans to engage 50 U.S. transplant centers for its GALACTIC registry study, which will help build a scientific case for the combined score of dd-cfDNA measurements [13]

Investor Presentation NASDAQ:IMDX March 2026 iMDxinc.com Forward-Looking Statements This presentation contains certain "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "target," "believe," "expect," "will," "may," "anticipate," "estimate," "would," "positioned," "future," and other similar expressions that predict or indicate future events or trends or t ...

Core Insights - Insight Molecular Diagnostics Inc. (iMDx) announced the results of a study demonstrating the effectiveness of its GraftAssure assay for long-term monitoring of kidney transplant patients with severe complications [1][4] - The study highlighted a unique case of a 33-year-old patient who developed lymphoma, requiring the cessation of traditional immunosuppression, and showed that GraftAssure testing confirmed the absence of organ rejection during treatment with novel CD19 CAR-T therapy [2][8] Study Findings - The patient maintained stable graft function for approximately two years without immunosuppression and remained in remission, indicating a potential "immune reset" due to the treatment [3][8] - GraftAssure's dd-cfDNA assay was identified as a reliable tool for confirming the absence of rejection in this rare clinical scenario, suggesting its growing importance in transplant care as novel therapies are introduced [4][9] Product Overview - The GraftAssure family of assays includes GraftAssureCore, which is currently reimbursed by Medicare and performed at a CLIA-certified laboratory, GraftAssureIQ for research use only, and GraftAssureDx, which is in development for clinical use [5][15] - The company anticipates that the clinical kitted version of its assay will provide significant value in the estimated $1 billion market for transplant rejection testing [5] Clinical Context - Post-transplantation lymphoproliferative disorder (PTLD) can arise from immunosuppression, complicating treatment for transplant patients [6] - The case study involved administering CD19 CAR-T therapy as a fourth-line treatment after previous therapies failed, showcasing the challenges faced in managing such patients [7] Future Implications - The findings from this study may position GraftAssure as essential in managing kidney transplant patients, particularly as the need for molecular monitoring of treatment effects is expected to grow [4][10]

Core Insights - Insight Molecular Diagnostics Inc. (iMDx) is actively participating in two significant industry conferences to showcase its GraftAssure™ technology and its clinical kitted test under development [1][4] - The company aims to highlight the clinical applications of transplant rejection testing, particularly in longitudinal surveillance and therapeutic response monitoring [2][3] Conference Participation - iMDx is hosting a symposium at the IATDMCT annual meeting in Singapore from September 21 to 24, 2025, focusing on the benefits of in-house testing for transplant rejection [2][6] - The company will also present at the ASHI annual meeting in Orlando, Florida, from October 6 to 10, 2025, discussing GraftAssureIQ, a research-use-only test kit [4][8] Technology and Product Development - GraftAssure technology is designed to detect transplant rejection and monitor treatment response, significantly reducing time-to-rejection diagnosis in high-risk kidney transplant patients [3][5] - The GraftAssureDx, currently in development, is expected to be submitted for FDA review by the end of 2025, targeting an estimated $1 billion addressable market for kitted transplant rejection testing [5][15] Strategic Partnerships - iMDx is collaborating with Bio-Rad Laboratories to present on GraftAssureIQ, emphasizing the potential of in-house testing for convenience and efficiency in transplant care [4][5] Market Position - The company is focused on democratizing access to molecular diagnostic testing, particularly for kidney transplant patients, utilizing donor-derived cell-free DNA (dd-cfDNA) as a biomarker for transplant rejection [16][13]

Core Insights - Insight Molecular Diagnostics (iMDx) announced two favorable oral abstracts, including a late-breaking study, to be presented at the World Transplant Congress from August 2 to 6, 2025, in San Francisco [1] Study Findings - The late-breaking study validated iMDx's novel approach to quantifying donor-derived cell-free DNA (dd-cfDNA), showing a positive predictive value (PPV) of 79% at a 25% rejection prevalence, significantly higher than the average 48% from published data [2] - The combined model of relative and absolute dd-cfDNA quantification was able to distinguish all types of rejection from non-rejection pathologies, indicating its dual utility in clinical decision-making [3][4] Clinical Implications - The improved PPV suggests that the dd-cfDNA combination model can serve as both a reliable tool to rule out organ rejection and a meaningful rule-in option, potentially changing the paradigm of dd-cfDNA testing [3] - iMDx's GraftAssure dd-cfDNA combination assay is positioned as an exceptionally useful biomarker for transplant physicians, addressing daily clinical challenges after kidney transplantation [4] Product Development - iMDx is working to bring the innovation into its CLIA lab and into its research-use-only and regulated clinical kitted product pipeline, enhancing diagnostic accuracy by combining two assays into one score [5] - The company is also developing GraftAssureDx and intends to seek regulatory authorization for clinical use, targeting the estimated $1 billion transplant rejection testing market [9] Upcoming Presentations - iMDx will present a second abstract at the World Transplant Congress, reaffirming dd-cfDNA as a noninvasive standard for predicting kidney transplant rejection, with the data selected for prominent discussion during the closing plenary session [6] Company Overview - iMDx, formerly known as Oncocyte Corp., is focused on democratizing access to novel molecular diagnostic testing to improve patient outcomes, with its GraftAssure product lines already achieving Medicare reimbursement [15][17]

Company Overview - Insight Molecular Diagnostics, or iMDx, is a pioneering diagnostics technology company focused on democratizing access to novel molecular diagnostic testing to improve patient outcomes [8] - The company recently moved its headquarters from Irvine, California, to Nashville, Tennessee, with a new NASDAQ symbol effective June 18, 2025 [9] Key Opinion Leader Event - iMDx will host a virtual key opinion leader (KOL) event on August 15, 2025, featuring Dr. Anthony Langone, who is the national principal investigator for iMDx's kidney transplant monitoring trial [1][2] - Dr. Langone will discuss the role of donor-derived cell-free DNA (dd-cfDNA) in transplant care and the benefits of in-house testing [2] GraftAssure™ Product Line - The GraftAssure™ family of assays utilizes advanced digital PCR (dPCR) technology to provide reliable dd-cfDNA results for transplant monitoring [3] - The company is developing a diagnostics test kit for clinical use, allowing hospitals to conduct their own tests in-house [3] - Current products include GraftAssureCore, a lab-developed test reimbursed by CMS, and GraftAssureIQ, a research-use-only kit [6][7] Future Developments - iMDx is working on GraftAssureDx, an in vitro diagnostic kit intended for clinical decision-making, which will be submitted for FDA authorization [7] - The company aims to commercialize its technology using a market-disruptive approach, establishing dd-cfDNA as a trusted biomarker for transplant rejection [6]

Core Insights - Insight Molecular Diagnostics (iMDx) announced positive results from a study comparing its GraftAssureIQ test kit with another commercially available test kit, showing equivalent measurements of donor-derived cell-free DNA (dd-cfDNA) [1][3][5] - The company aims to launch its first clinical molecular diagnostic test kit, targeting the estimated $1 billion transplant rejection testing market [2][15] - The study, conducted by the University Hospital Heidelberg, represents the first direct comparison of two commercially available dd-cfDNA test kits, one using next-generation sequencing (NGS) and the other using digital polymerase chain reaction (digital PCR) [4][5] Study Details - The study evaluated 96 kidney transplant recipients and demonstrated that both platforms provided consistent results, reinforcing the reliability of dd-cfDNA testing in routine transplant care [5][8] - Digital PCR showed improved analytical sensitivity compared to NGS, suggesting potential advantages in detecting dd-cfDNA in low quantities [3][5] - Extended data from the study will be presented at the upcoming European Society of Organ Transplantation (ESOT) Congress in London [7][8] Product Development - GraftAssureIQ is currently a research-use-only kit, while iMDx is developing GraftAssureDx for clinical use and intends to seek regulatory authorization [6][16] - The company has transitioned its headquarters from Irvine, California, to Nashville, Tennessee, and its NASDAQ symbol changed to IMDX [14] - iMDx's transplant diagnostics include GraftAssureCore, which is a lab-developed test currently reimbursed by CMS [15]

Core Insights - Insight Molecular Diagnostics Inc. has rebranded from Oncocyte Corporation and relocated its headquarters to Nashville, Tennessee, with a new stock symbol "IMDX" effective June 18, 2025 [1][2][3] Company Strategy - The rebranding reflects the company's expanded strategic direction beyond oncology, now including a focus on transplant medicine, aiming to deliver a molecular diagnostic kit for kidney transplant patients [2][3] - The company targets a $1 billion addressable market for transplant rejection testing and is transitioning from product development to commercialization [3][4] Operational Changes - The relocation to Nashville aligns operations with the company's CLIA-certified lab and healthcare innovation hub, while maintaining a laboratory in Göttingen, Germany [4] - The company is unifying its transplant diagnostics under the GraftAssure brand, retiring the VitaGraft name [11][16] Product Development - The GraftAssure product line includes GraftAssureCore (lab-developed test), GraftAssureIQ (research-use-only kit), and GraftAssureDx (in vitro diagnostic kit in development) [11][12][16] - The company is actively participating in the European Society for Organ Transplantation (ESOT) Congress to promote its GraftAssureIQ pilot site program [7][9] Branding and Identity - The new logo symbolizes the company's commitment to healthcare providers and reflects its mission to provide insights through science [5][6] - The rebranding leverages existing rights to the name Insight Genetics, acquired in 2020, and emphasizes a healthcare provider-centric philosophy [5][6]

Core Insights - Oncocyte Corp. has announced a positive update regarding the pricing of its next-generation lab-developed test (LDT), GraftAssureCore, which enhances its position in the transplant rejection testing market and indicates potential growth in its estimated $1 billion total addressable market [1][6] Pricing and Reimbursement - The Centers for Medicare & Medicaid Services (CMS) has increased the reimbursement rate for GraftAssureCore to $2,753 per result, up from $2,222 for first-time testing and $1,029 for subsequent tests [2] - This new pricing aligns with existing competitive technologies and expands market appeal for future FDA-cleared kitted products at transplant centers [6] Company Strategy and Future Prospects - Oncocyte has invested significantly in improving the scalability and manufacturability of its workflow, which supports its kitted test program [3] - The new reimbursement rate establishes a benchmark for future kitted tests, such as GraftAssureDx, which is expected to be submitted for FDA review by the end of the year [3] - The company anticipates that receiving FDA authorization will enable broader adoption of its technology, allowing transplant centers to access high-quality, FDA-cleared kits with established reimbursement [4] Clinical Trials and Market Engagement - Oncocyte has received approval from a Central Institutional Review Board for its clinical trial, with final preparations underway at participating transplant centers [4] - The company expects participation from three of the top 10 U.S. transplant centers, representing nearly 10% of annual U.S. transplant volume [4] Technology and Market Position - Oncocyte's technology quantifies donor-derived cell-free DNA (dd-cfDNA), which has been established as a trusted biomarker for transplant rejection [5] - The company is rebranding its test portfolio under the GraftAssure brand, with GraftAssureCore being the new name for its previously marketed VitaGraft assay [5]